Pharming Group NV (PHAR) — Capital Reinvestment Ratio
Pharming Group NV (PHAR) has a Capital Reinvestment Ratio of 0.15x as of March 2026, meaning it reinvests 0% of its operating cash flow ($1.63 Million) in capital expenditures ($238.86K). See debt-free asset ratio of Pharming Group NV to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Pharming Group NV Capital Reinvestment Ratio (2017–2025)
This chart tracks Pharming Group NV's Capital Reinvestment Ratio across 7 annual periods. Check how aggressively does Pharming Group NV reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Pharming Group NV (2017–2025)
Year-by-year Capital Reinvestment Ratio for Pharming Group NV from 2017 to 2025. For live market cap and broader valuation context, see Pharming Group NV (PHAR) total market value.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.02x | $50.07 Million | $751.09K | ▼ -83.0% |
| 2022 | 0.09x | $22.46 Million | $1.98 Million | ▼ -80.1% |
| 2021 | 0.44x | $37.84 Million | $16.72 Million | ▲ +141.4% |
| 2020 | 0.18x | $83.63 Million | $15.30 Million | ▼ -46.7% |
| 2019 | 0.34x | $74.15 Million | $25.45 Million | ▲ +267.7% |
| 2018 | 0.09x | $46.19 Million | $4.31 Million | ▼ -41.0% |
| 2017 | 0.16x | $45.84 Million | $7.25 Million | — |